OBJECTIVE: Central nervous system (CNS) features in children with permanent neonatal diabetes (PNDM) due to KCNJ11 mutations have a major impact on affected families. Sulfonylurea therapy achieves outstanding metabolic control but only partial improvement in CNS features. The effects of KCNJ11 mutations on the adult brain and their functional impact are not well understood. We aimed to characterize the CNS features in adults with KCNJ11 PNDM compared with adults with INS PNDM. RESEARCH DESIGN AND METHODS: Adults with PNDM due to KCNJ11 mutations (n = 8) or INS mutations (n = 4) underwent a neurological examination and completed standardized neuropsychological tests/questionnaires about development/behavior. Four individuals in each group underwent a brain MRI scan. Test scores were converted to Z scores using normative data, and outcomes were compared between groups. RESULTS: In individuals with KCNJ11 mutations, neurological examination was abnormal in seven of eight; predominant features were subtle deficits in coordination/motor sequencing. All had delayed developmental milestones and/or required learning support/special schooling. Half had features and/or a clinical diagnosis of autism spectrum disorder. KCNJ11 mutations were also associated with impaired attention, working memory, and perceptual reasoning and reduced intelligence quotient (IQ) (median IQ KCNJ11 vs. INS mutations 76 vs. 111, respectively; P = 0.02). However, no structural brain abnormalities were noted on MRI. The severity of these features was related to the specific mutation, and they were absent in individuals with INS mutations. CONCLUSIONS: KCNJ11 PNDM is associated with specific CNS features that are not due to long-standing diabetes, persist into adulthood despite sulfonylurea therapy, and represent the major burden from KCNJ11 mutations.
OBJECTIVE: Central nervous system (CNS) features in children with permanent neonatal diabetes (PNDM) due to KCNJ11 mutations have a major impact on affected families. Sulfonylurea therapy achieves outstanding metabolic control but only partial improvement in CNS features. The effects of KCNJ11 mutations on the adult brain and their functional impact are not well understood. We aimed to characterize the CNS features in adults with KCNJ11 PNDM compared with adults with INS PNDM. RESEARCH DESIGN AND METHODS: Adults with PNDM due to KCNJ11 mutations (n = 8) or INS mutations (n = 4) underwent a neurological examination and completed standardized neuropsychological tests/questionnaires about development/behavior. Four individuals in each group underwent a brain MRI scan. Test scores were converted to Z scores using normative data, and outcomes were compared between groups. RESULTS: In individuals with KCNJ11 mutations, neurological examination was abnormal in seven of eight; predominant features were subtle deficits in coordination/motor sequencing. All had delayed developmental milestones and/or required learning support/special schooling. Half had features and/or a clinical diagnosis of autism spectrum disorder. KCNJ11 mutations were also associated with impaired attention, working memory, and perceptual reasoning and reduced intelligence quotient (IQ) (median IQ KCNJ11 vs. INS mutations 76 vs. 111, respectively; P = 0.02). However, no structural brain abnormalities were noted on MRI. The severity of these features was related to the specific mutation, and they were absent in individuals with INS mutations. CONCLUSIONS: KCNJ11 PNDM is associated with specific CNS features that are not due to long-standing diabetes, persist into adulthood despite sulfonylurea therapy, and represent the major burden from KCNJ11 mutations.
Authors: P Bowman; A T Hattersley; B A Knight; E Broadbridge; L Pettit; M Reville; S E Flanagan; M H Shepherd; T J Ford; J Tonks Journal: Diabet Med Date: 2017-08 Impact factor: 4.359
Authors: Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: A S Slingerland; W Hurkx; K Noordam; S E Flanagan; J W Jukema; L C Meiners; G J Bruining; A T Hattersley; M Hadders-Algra Journal: Diabet Med Date: 2008-03 Impact factor: 4.359
Authors: D Carmody; A N Pastore; K A Landmeier; L R Letourneau; R Martin; J L Hwang; R N Naylor; S J Hunter; M E Msall; L H Philipson; M N Scott; S A W Greeley Journal: Diabet Med Date: 2016-06-22 Impact factor: 4.359
Authors: Rebecca H Clark; James S McTaggart; Richard Webster; Roope Mannikko; Michaela Iberl; Xiu Li Sim; Patrik Rorsman; Maike Glitsch; David Beeson; Frances M Ashcroft Journal: Science Date: 2010-07-01 Impact factor: 47.728
Authors: P Bowman; E Broadbridge; B A Knight; L Pettit; S E Flanagan; M Reville; J Tonks; M H Shepherd; T J Ford; A T Hattersley Journal: Diabet Med Date: 2016-05-21 Impact factor: 4.359
Authors: J O Day; S E Flanagan; M H Shepherd; A W Patrick; N Abid; L Torrens; A J Zeman; K A Patel; A T Hattersley Journal: Diabet Med Date: 2017-07 Impact factor: 4.359
Authors: Elisa De Franco; Cécile Saint-Martin; Klaus Brusgaard; Amy E Knight Johnson; Lydia Aguilar-Bryan; Pamela Bowman; Jean-Baptiste Arnoux; Annette Rønholt Larsen; May Sanyoura; Siri Atma W Greeley; Raúl Calzada-León; Bradley Harman; Jayne A L Houghton; Elisa Nishimura-Meguro; Thomas W Laver; Sian Ellard; Daniela Del Gaudio; Henrik Thybo Christesen; Christine Bellanné-Chantelot; Sarah E Flanagan Journal: Hum Mutat Date: 2020-02-17 Impact factor: 4.878
Authors: Shaul Yahil; David F Wozniak; Zihan Yan; Steven Mennerick; Maria S Remedi Journal: Proc Natl Acad Sci U S A Date: 2021-11-09 Impact factor: 11.205